The biology and pathology of the familial Parkinson's disease protein LRRK2
Identifieur interne : 001227 ( Main/Corpus ); précédent : 001226; suivant : 001228The biology and pathology of the familial Parkinson's disease protein LRRK2
Auteurs : William Dauer ; Cherry Cheng-Ying HoSource :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22717
Links to Exploration step
ISTEX:758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The biology and pathology of the familial Parkinson's disease protein LRRK2</title><author><name sortKey="Dauer, William" sort="Dauer, William" uniqKey="Dauer W" first="William" last="Dauer">William Dauer</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Ho, Cherry Cheng Ing" sort="Ho, Cherry Cheng Ing" uniqKey="Ho C" first="Cherry Cheng-Ying" last="Ho">Cherry Cheng-Ying Ho</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22717</idno><idno type="url">https://api.istex.fr/document/758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001227</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The biology and pathology of the familial Parkinson's disease protein LRRK2</title><author><name sortKey="Dauer, William" sort="Dauer, William" uniqKey="Dauer W" first="William" last="Dauer">William Dauer</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmacology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Ho, Cherry Cheng Ing" sort="Ho, Cherry Cheng Ing" uniqKey="Ho C" first="Cherry Cheng-Ying" last="Ho">Cherry Cheng-Ying Ho</name><affiliation><mods:affiliation>Department of Neurology, Columbia University, New York, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S40">S40</biblScope><biblScope unit="page" to="S43">S43</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683</idno><idno type="DOI">10.1002/mds.22717</idno><idno type="ArticleID">MDS22717</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>LRRK2</term><term>Parkinson's disease</term><term>neurodegeneration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>William Dauer MD</name><affiliations><json:string>Department of Neurology, Columbia University, New York, New York, USA</json:string><json:string>Department of Pharmacology, Columbia University, New York, New York, USA</json:string></affiliations></json:item><json:item><name>Cherry Cheng‐Ying Ho</name><affiliations><json:string>Department of Neurology, Columbia University, New York, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegeneration</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>LRRK2</value></json:item></subject><articleId><json:string>MDS22717</json:string></articleId><language><json:string>eng</json:string></language><abstract>Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>4.117</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>869</abstractCharCount><pdfWordCount>2605</pdfWordCount><pdfCharCount>17089</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>126</abstractWordCount></qualityIndicators><title>The biology and pathology of the familial Parkinson's disease protein LRRK2</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>S43</last><first>S40</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><author><json:item><name>Fahn Stanley MD</name></json:item><json:item><name>Marder Karen MD</name></json:item><json:item><name>Côté Lucien MD</name></json:item><json:item><name>Reich Stephen G. MD</name></json:item></author><subject><json:item><value>Pathogenesis and Implications for Neuroprotection</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22717</json:string></doi><id>758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The biology and pathology of the familial Parkinson's disease protein LRRK2</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>Parkinson's Disease Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The biology and pathology of the familial Parkinson's disease protein LRRK2</title><author><persName><forename type="first">William</forename><surname>Dauer</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Departments of Neurology and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109</p></note><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Pharmacology, Columbia University, New York, New York, USA</affiliation></author><author><persName><forename type="first">Cherry Cheng‐Ying</forename><surname>Ho</surname></persName><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S40">S40</biblScope><biblScope unit="page" to="S43">S43</biblScope></imprint></monogr><idno type="istex">758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683</idno><idno type="DOI">10.1002/mds.22717</idno><idno type="ArticleID">MDS22717</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>neurodegeneration</term></item><item><term>LRRK2</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Pathogenesis and Implications for Neuroprotection</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-07-11">Received</change><change when="2009-07-06">Registration</change><change when="2010">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="5"><doi origin="wiley" registered="yes">10.1002/mds.v25.1s</doi><titleGroup><title type="specialIssueTitle">Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">S1</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Fahn</givenNames><familyName>Stanley</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Marder</givenNames><familyName>Karen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Côté</givenNames><familyName>Lucien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped4" creatorRole="sponsoringEditor"><personName><givenNames>Reich</givenNames><familyName>Stephen G.</familyName><degrees>MD</degrees></personName></creator></creators><coverDate startDate="2010">2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22717</doi><idGroup><id type="unit" value="MDS22717"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Pathogenesis and Implications for Neuroprotection</title><title type="tocHeading1">Pathogenesis and Implications for Neuroprotection</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-07-11"></event><event type="manuscriptAccepted" date="2009-07-06"></event><event type="firstOnline" date="2010-02-25"></event><event type="publishedOnlineFinalForm" date="2010-02-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S40</numbering><numbering type="pageLast">S43</numbering></numberingGroup><correspondenceTo>Departments of Neurology and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22717.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="51"></count><count type="wordTotal" number="2583"></count></countGroup><titleGroup><title type="main" xml:lang="en">The biology and pathology of the familial Parkinson's disease protein LRRK2<link href="#fn1"></link></title><title type="short" xml:lang="en">Familial PD Protein LRRK2</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>William</givenNames><familyName>Dauer</familyName><degrees>MD</degrees></personName><contactDetails><email>dauer@umich.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cherry Cheng‐Ying</givenNames><familyName>Ho</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Pharmacology, Columbia University, New York, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">neurodegeneration</keyword><keyword xml:id="kwd3">LRRK2</keyword></keywordGroup><fundingInfo><fundingAgency>Parkinson's Disease Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The biology and pathology of the familial Parkinson's disease protein LRRK2</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Familial PD Protein LRRK2</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The biology and pathology of the familial Parkinson's disease protein LRRK2</title></titleInfo><name type="personal"><namePart type="given">William</namePart><namePart type="family">Dauer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation><affiliation>Department of Pharmacology, Columbia University, New York, New York, USA</affiliation><description>Correspondence: Departments of Neurology and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cherry Cheng‐Ying</namePart><namePart type="family">Ho</namePart><affiliation>Department of Neurology, Columbia University, New York, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010</dateIssued><dateCaptured encoding="w3cdtf">2008-07-11</dateCaptured><dateValid encoding="w3cdtf">2009-07-06</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="references">51</extent><extent unit="words">2583</extent></physicalDescription><abstract lang="en">Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">Parkinson's Disease Foundation</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>neurodegeneration</topic><topic>LRRK2</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Fahn</namePart><namePart type="family">Stanley</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Marder</namePart><namePart type="family">Karen</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Côté</namePart><namePart type="family">Lucien</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Reich</namePart><namePart type="family">Stephen G.</namePart><namePart type="termsOfAddress">MD</namePart></name><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Pathogenesis and Implications for Neuroprotection</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="title"><title>Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><extent unit="pages"><start>S40</start><end>S43</end><total>4</total></extent></part></relatedItem><identifier type="istex">758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683</identifier><identifier type="DOI">10.1002/mds.22717</identifier><identifier type="ArticleID">MDS22717</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001227 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001227 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:758F518B9D51EBDB4D02C2B1F2F86C5C4AA67683
|texte= The biology and pathology of the familial Parkinson's disease protein LRRK2
}}
| This area was generated with Dilib version V0.6.23. |  |